Mass spectrometry-driven advances in blood-based biomarkers for Alzheimer’s disease: A mini-review

Abstract

The core pathological characteristics of Alzheimer’s disease (AD) are characterized by the deposition of β-amyloid plaques and the formation of tau protein neurofibrillary tangles. Clinical diagnosis predominantly relies on cerebrospinal fluid analysis or positron emission tomography. However, these methods are associated with the risks of invasive procedures and significant cost constraints. Mass spectrometry, with its high sensitivity (reaching the femtogram level) and capability for multiplex detection, facilitates not only the precise quantification of AD biomarkers in blood but also offers a cost-effective solution. This review systematically elucidates the advancements in the clinical application of mass spectrometry technology for risk assessment, early diagnosis, and therapeutic monitoring of AD. It also highlights recent breakthroughs in identifying novel blood biomarkers using mass spectrometry technology and a multi-omics integration strategy.

Keywords

Mass spectrometry / Alzheimer’s disease / Blood-based biomarkers / Amyloid β-protein / p-Tau

Funding

This work was supported by The Key Program of Jiangsu Geriatric Health Research (grant number: BK20242002).

Conflict of interest

The authors declare that they have no competing interests.

References

[1] 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020; 16:391-460. doi: 10.1002/alz.12068

[2] Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell. 2019; 179(2):312-339. doi: 10.1016/j.cell.2019.09.001

[3] Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Alonso Adel C, Tau-induced neurodegeneration: Mechanisms and targets. Neurosci Bull. 2014; 30(2):346-358. doi: 10.1007/s12264-013-1414-z

[4] Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021; 8(3):371-386. doi: 10.14283/jpad.2021.23

[5] Varghese T, Sheelakumari R, James JS, Mathuranath PS. A review of neuroimaging biomarkers of Alzheimer’s disease. Neurol Asia. 2013; 18(3):239-248.

[6] Anoop A, Singh PK, Jacob RS, Maji SK. CSF biomarkers for Alzheimer’s disease diagnosis. Int J Alzheimers Dis. 2010; 2010:606802. doi: 10.4061/2010/606802

[7] Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020;11(1):1683. doi: 10.1038/s41467-020-15436-0

[8] Duits FH, Martinez-Lage P, Paquet C, et al. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016; 12(2):154-163. doi: 10.1016/j.jalz.2015.08.003

[9] Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer’s disease in clinical practice and trials. Nat Aging. 2023; 3(5):506-519. doi: 10.1038/s43587-023-00403-3

[10] Hampel H, Hu Y, Cummings J, et al. Blood-based biomarkers for Alzheimer’s disease: Current State and future use in a transformed global healthcare landscape. Neuron. 2023; 111(18):2781-2799. doi: 10.1016/j.neuron.2023.05.017

[11] Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78(11): 1375-1382. doi: 10.1001/jamaneurol.2021.3180

[12] Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018; 554(7691):249-254. doi: 10.1038/nature25456

[13] Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647-e1659. doi: 10.1212/wnl.0000000000008081

[14] Rissman RA, Langford O, Raman R, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimers Dement. 2024;20(2): 1214-1224. doi: 10.1002/alz.13542

[15] Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology. Alzheimers Dement. 2024; 20(11):8074-8096. doi: 10.1002/alz.14315

[16] Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. 2023; 146(4):1592-1601. doi: 10.1093/brain/awac333

[17] Jack CR Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s association workgroup. Alzheimers Dement. 2024; 20(8):5143-5169. doi: 10.1002/alz.13859

[18] Cummings JL, Cole G. Alzheimer disease. JAMA. 2002; 287(18):2335-2338. doi: 10.1001/jama.287.18.2335

[19] Korecka M, Shaw LM. Mass spectrometry-based methods for robust measurement of Alzheimer’s disease biomarkers in biological fluids. J Neurochem. 2021; 159(2):211-233. doi: 10.1111/jnc.15465

[20] Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017; 13(8):841-849. doi: 10.1016/j.jalz.2017.06.2266

[21] Pannee J, Törnqvist U, Westerlund A, et al. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer’s disease. Neurosci Lett. 2014;573: 7-12. doi: 10.1016/j.neulet.2014.04.041

[22] Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimers Dement. 2022;18(2): 283-293. doi: 10.1002/alz.12395

[23] Pontecorvo MJ, Lu M, Burnham SC, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022; 79(12):1250-1259. doi: 10.1001/jamaneurol.2022.3392

[24] Howe MD, Britton KJ, Joyce HE, et al. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease. Alzheimers Res Ther. 2024; 16(1):154. doi: 10.1186/s13195-024-01521-9

[25] Bai B, Wang X, Li Y, et al. Deep multilayer brain proteomics identifies molecular networks in Alzheimer’s disease progression. Neuron. 2020; 105(6):975-991.e7. doi: 10.1016/j.neuron.2019.12.015

[26] Lacar B, Ferdosi S, Alavi A, et al. Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias using Unbiased Plasma Proteomics. bioRxiv [Preprint]; 2024. doi: 10.1101/2024.01.05.574446

[27] Horie K, Salvadó G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nat Med. 2025;31(6): 2044-2053. doi: 10.1038/s41591-025-03617-7